1. Jung SH. Stroke rehabilitation fact sheet in Korea. Ann Rehabil Med. 2022; 46:1–8.
Article
2. Kuo CL, Hu GC. Post-stroke spasticity: a review of epidemiology, pathophysiology, and treatments. Int J Gerontol. 2018; 12:280–4.
Article
3. Sunnerhagen KS, Olver J, Francisco GE. Assessing and treating functional impairment in poststroke spasticity. Neurology. 2013; 80(3 Suppl 2):S35–44.
Article
4.
CS Kim
KY Song
KM Min
YD An
. Method for production of botulinum toxin. World patent WO. 2015/016462 (KR2014/004003). 2015. Feb. 5.
5. Kim CS, Jang WS, Son IP, Nam SH, Kim YI, Park KY, et al. Electrophysiological study for comparing the effect of biological activity between type A botulinum toxins in rat gastrocnemius muscle. Hum Exp Toxicol. 2013; 32:914–20.
Article
6. Nam HS, Park YG, Paik NJ, Oh BM, Chun MH, Yang HE, et al. Efficacy and safety of NABOTA in post-stroke upper limb spasticity: a phase 3 multicenter, double-blinded, randomized controlled trial. J Neurol Sci. 2015; 357:192–7.
Article
7. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987; 67:206–7.
Article
8. Brashear A, Zafonte R, Corcoran M, Galvez-Jimenez N, Gracies JM, Gordon MF, et al. Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil. 2002; 83:1349–54.
Article
9. Elmstahl S, Malmberg B, Annerstedt L. Caregiver’s burden of patients 3 years after stroke assessed by a novel caregiver burden scale. Arch Phys Med Rehabil. 1996; 77:177–82.
Article
10. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry. 2000; 69:217–21.
Article
11. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002; 347:395–400.
Article
12. Seo HG, Paik NJ, Lee SU, Oh BM, Chun MH, Kwon BS, et al. Neuronox versus BOTOX in the treatment of post-stroke upper limb spasticity: a multicenter randomized controlled trial. PLoS One. 2015; 10:e0128633.
Article
14. Ney JP, Joseph KR. Neurologic uses of botulinum neurotoxin type A. Neuropsychiatr Dis Treat. 2007; 3:785–98.
Article
15. Rousseaux M, Kozlowski O, Froger J. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients. J Neurol. 2002; 249:76–84.
Article
16. Shaw LC, Price CI, van Wijck FM, Shackley P, Steen N, Barnes MP, et al. Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial: effect on impairment, activity limitation, and pain. Stroke. 2011; 42:1371–9.
Article
17. Dunne JW, Heye N, Dunne SL. Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry. 1995; 58:232–5.
Article
18. Bergfeldt U, Borg K, Kullander K, Julin P. Focal spasticity therapy with botulinum toxin: effects on function, activities of daily living and pain in 100 adult patients. J Rehabil Med. 2006; 38:166–71.
Article
19. Cardoso E, Rodrigues B, Lucena R, Oliveira IR, Pedreira G, Melo A. Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis. Arq Neuropsiquiatr. 2005; 63:30–3.
Article